Public Sector Pension Investment Board Has $14.87 Million Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• The Public Sector Pension Investment Board increased its holdings in ADMA Biologics by 27.3% during the first quarter, acquiring a total of 749,702 shares valued at approximately $14.87 million.
• Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics, resulting in a 2.05% decrease in his ownership, while insider selling has totaled 464,621 shares over the last 90 days.
• ADMA Biologics reported earnings of $0.15 per share for the last quarter, exceeding analysts' expectations, with a revenue of $121.98 million marking a 13.8% year-over-year increase.

Public Sector Pension Investment Board raised its position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 27.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 749,702 shares of the biotechnology company's stock after purchasing an additional 160,762 shares during the period. Public Sector Pension Investment Board owned about 0.32% of ADMA Biologics worth $14,874,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. New York State Teachers Retirement System lifted its holdings in shares of ADMA Biologics by 96.2% in the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock valued at $4,402,000 after buying an additional 108,800 shares during the period. GAMMA Investing LLC increased its stake in ADMA Biologics by 251.6% during the 1st quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock worth $131,000 after buying an additional 4,715 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new stake in ADMA Biologics during the 1st quarter worth approximately $201,000. Ameriprise Financial Inc. grew its position in shares of ADMA Biologics by 14.1% in the fourth quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company's stock valued at $12,274,000 after purchasing an additional 88,542 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in shares of ADMA Biologics in the first quarter valued at approximately $2,293,000. 75.68% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock valued at $9,644,269 in the last ninety days. Company insiders own 3.50% of the company's stock.

ADMA Biologics Price Performance

Shares of ADMA stock traded up $0.02 during midday trading on Friday, reaching $16.99. 3,108,545 shares of the company traded hands, compared to its average volume of 3,534,720. The firm's 50 day simple moving average is $18.29 and its two-hundred day simple moving average is $18.85. ADMA Biologics Inc has a 1-year low of $13.50 and a 1-year high of $25.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The firm has a market cap of $4.05 billion, a PE ratio of 19.76 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%. The company's quarterly revenue was up 13.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.13 EPS. On average, equities research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on ADMA. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial increased their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.